Korean red ginseng extract attenuates 3-nitropropionic acid-induced Huntington's-like symptoms

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Jang, Minhee ^a   Lee, Min Jung ^a   Kim, Cheon Suk ^b   Cho, Ik Hyun ^a  

^a Kyung Hee University   (South Korea)

^b Korea Ginseng Corporation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 NITROPROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GINSENG EXTRACT; GINSENOSIDE RB 1; GINSENOSIDE RG 1; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; KOREAN RED GINSENG EXTRACT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPROTECTIVE AGENT; OX 42 PROTEIN; PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL ACTIVATION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GINSENG; HUNTINGTON CHOREA; LETHALITY; MALE; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84874516526     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/237207     Document Type: Article

References (70)

1. Damiano M., Galvan L., Déglon N., Brouillet E., Mitochondria in Huntington's disease. Biochimica et Biophysica Acta 2010 1802 1 52 61 2-s2.0-71949108518 10.1016/j.bbadis.2009.07.012
2. MacDonald M. E., Ambrose C. M., Duyao M. P., Myers R. H., Lin C., Srinidhi L., Barnes G., Taylor S. A., James M., Groot N., MacFarlane H., Jenkins B., Anderson M. A., Wexler N. S., Gusella J. F., Bates G. P., Baxendale S., Hummerich H., Kirby S., A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993 72 6 971 983 2-s2.0-0027480960 10.1016/0092-8674(93)90585-E (Pubitemid 23110238)
3. Ryu J. K., Kim S. U., McLarnon J. G., Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease. Experimental Neurology 2004 187 1 150 159 2-s2.0-1842814974 10.1016/j.expneurol.2004.01.006 (Pubitemid 38470020)
4. Tai Y. F., Pavese N., Gerhard A., Tabrizi S. J., Barker R. A., Brooks D. J., Piccini P., Imaging microglial activation in Huntington's disease. Brain Research Bulletin 2007 72 2-3 148 151 2-s2.0-33847788629 10.1016/j.brainresbull. 2006.10.029 (Pubitemid 46389550)
5. Leegwater-Kim J., Cha J. H. J., The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRx 2004 1 1 128 138 2-s2.0-15944413899 10.1602/neurorx.1.1.128 (Pubitemid 46589346)
6. Block M. L., Hong J. S., Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochemical Society Transactions 2007 35 5 1127 1132 2-s2.0-36749051047 10.1042/BST0351127 (Pubitemid 350206444)
7. Lobsiger C. S., Cleveland D. W., Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nature Neuroscience 2007 10 11 1355 1360 2-s2.0-35549006420 10.1038/nn1988 (Pubitemid 350014678)
8. Sapp E., Kegel K. B., Aronin N., Hashikawa T., Uchiyama Y., Tohyama K., Bhide P. G., Vonsattel J. P., Difiglia M., Early and progressive accumulation of reactive microglia in the Huntington disease brain. Journal of Neuropathology and Experimental Neurology 2001 60 2 161 172 2-s2.0-0035111235 (Pubitemid 32172419)
9. Simmons D. A., Casale M., Alcon B., Pham N., Narayan N., Lynch G., Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's Disease. GLIA 2007 55 10 1074 1084 2-s2.0-34447520021 10.1002/glia.20526 (Pubitemid 47066747)
10. Björkqvist M., Wild E. J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R. V., Benn C. L., Soulet D., Magnusson A., Woodman B., Landles C., Pouladi M. A., Hayden M. R., Khalili-Shirazi A., Lowdell M. W., Brundin P., Bates G. P., Leavitt B. R., Möller T., Tabrizi S. J., A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. Journal of Experimental Medicine 2008 205 8 1869 1877 2-s2.0-49249089029 10.1084/jem.20080178
11. Harper S. J., Wilkie N., MAPKs: new targets for neurodegeneration. Expert Opinion on Therapeutic Targets 2003 7 2 187 200 2-s2.0-0037399165 10.1517/14728222.7.2.187 (Pubitemid 36512020)
12. Mattson M. P., Camandola S., NF- B in neuronal plasticity and neurodegenerative disorders. Journal of Clinical Investigation 2001 107 3 247 254 2-s2.0-0034746288
13. Yau L., Zahradka P., Immunodetection of activated mitogen-activated protein kinase in vascular tissues. Molecular and Cellular Biochemistry 1997 172 1-2 59 66 2-s2.0-0030773239 10.1023/A:1006807303088 (Pubitemid 27374574)
14. Haddad J. J., N-methyl-D-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: a revolving neurochemical axis for therapeutic intervention? Progress in Neurobiology 2005 77 4 252 282 2-s2.0-29044449313 10.1016/j.pneurobio.2005.10.008 (Pubitemid 41790443)
15. Fan J., Gladding C. M., Wang L., Zhang L. Y. J., Kaufman A. M., P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiology of Disease 2012 45 3 999 1009 10.1016/j.nbd.2011.12.019
16. Liu Y. F., Dorow D., Marshall J., Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin. Journal of Biological Chemistry 2000 275 25 19035 19040 2-s2.0-0001583878 10.1074/jbc.C000180200 (Pubitemid 30422870)
17. Sugino T., Nozaki K., Hashimoto N., Activation of mitogen-activated protein kinases in gerbil hippocampus with ischemic tolerance induced by 3-nitropropionic acid. Neuroscience Letters 2000 278 1-2 101 104 2-s2.0-0033987107 10.1016/S0304-3940(99)00906-4 (Pubitemid 30009907)
18. Garcia M., Vanhoutte P., Pages C., Besson M. J., Brouillet E., Caboche J., The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. Journal of Neuroscience 2002 22 6 2174 2184 2-s2.0-0037088935 (Pubitemid 35386517)
19. Garcia M., Charvin D., Caboche J., Expanded huntingtin activates the C-Jun N terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture. Neuroscience 2004 127 4 859 870 2-s2.0-4143112468 10.1016/j.neuroscience.2004.05.054 (Pubitemid 39099551)
20. Apostol B. L., Illes K., Pallos J., Bodai L., Wu J., Strand A., Schweitzer E. S., Olson J. M., Kazantsev A., Marsh J. L., Thompson L. M., Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Human Molecular Genetics 2006 15 2 273 285 2-s2.0-31144472414 10.1093/hmg/ddi443 (Pubitemid 43125981)
21. Chu C. T., Levinthal D. J., Kulich S. M., Chalovich E. M., DeFranco D. B., Oxidative neuronal injury: the dark side of ERK1/2. European Journal of Biochemistry 2004 271 11 2060 2066 2-s2.0-2942517676 10.1111/j.1432-1033.2004. 04132.x (Pubitemid 38747975)
22. Hetman M., Gosdz A., Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. European Journal of Biochemistry 2004 271 11 2050 2055 10.1111/j.1432-1033.2004.04133.x (Pubitemid 38747973)
23. Ferrer I., Blanco R., Carmona M., Differential expression of active, phosphorylation-dependent MAP kinases, MAPK/ERK, SAPK/JNK and p38, and specific transcription factor substrates following quinolinic acid excitotoxicity in the rat. Molecular Brain Research 2001 94 1-2 48 58 2-s2.0-0035914189 10.1016/S0169-328X(01)00198-X (Pubitemid 32964745)
24. Gianfriddo M., Melani A., Turchi D., Giovannini M. G., Pedata F., Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiology of Disease 2004 17 1 77 88 2-s2.0-4444380899 10.1016/j.nbd.2004.05.008 (Pubitemid 39209315)
25. Qin Z. H., Chen R. W., Wang Y., Nakai M., Chuang D. M., Chase T. N., Nuclear factor B nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. Journal of Neuroscience 1999 19 10 4023 4033 2-s2.0-0033561799 (Pubitemid 29222275)
26. Choi K. T., Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacologica Sinica 2008 29 9 1109 1118 2-s2.0-51349106992 10.1111/j.1745-7254.2008.00869.x
27. Shibata S., Fujita M., Itokawa H., Tanaka O., Ishii T., Studies on the constituents of Japanese and Chinese crude drugs. Xi. Panaxadiol, a Sapogenin of Ginseng Roots. Chemical & Pharmaceutical Bulletin 1963 11 759 761
28. Xiaoguang C., Hongyan L., Xiaohong L., Zhaodi F., Yan L., Lihua T., Rui H., Cancer chemopreventive and therapeutic activities of red ginseng. Journal of Ethnopharmacology 1998 60 1 71 78 2-s2.0-0031933812 10.1016/S0378-8741(97) 00133-5 (Pubitemid 28098342)
29. Oh S. H., Lee B. H., A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and Bid cleavage. Toxicology and Applied Pharmacology 2004 194 3 221 229 2-s2.0-0842264760 10.1016/j.taap.2003.09.011 (Pubitemid 38175284)
30. Jang H. I., Shin H. M., Wild Panax ginseng (Panax ginseng C.A. Meyer) protects against methotrexate-induced cell regression by enhancing the immune response in RAW 264.7 macrophages. American Journal of Chinese Medicine 2010 38 5 949 960 2-s2.0-77956432021 10.1142/S0192415X10008378
31. Radad K., Gille G., Liu L., Rausch W. D., Use of ginseng in medicine with emphasis on neurodegenerative disorders. Journal of Pharmacological Sciences 2006 100 3 175 186 2-s2.0-33645058893 10.1254/jphs.CRJ05010X
32. Cho I.-H., Efects of Panax ginseng in neurodegenerative diseases. Journal of Ginseng Research 2012 36 4 342 353 10.5142/jgr.2012.36.4.342
33. Benishin C. G., Actions of ginsenoside Rb1 on choline uptake in central cholinergic nerve endings. Neurochemistry International 1992 21 1 1 5 2-s2.0-0026615912 10.1016/0197-0186(92)90061-U
34. Rudakewich M., Ba F., Benishin C. G., Neurotrophic and neuroprotective actions of ginsenosides Rb1and Rg1. Planta Medica 2001 67 6 533 537 2-s2.0-0034868729 10.1055/s-2001-16488 (Pubitemid 32800419)
35. Cha H. Y., Park J. H., Hong J. T., Yoo H. S., Song S., Hwang B. Y., Eun J. S., Oh K. W., Anxiolytic-like effects of ginsenosides on the elevated plus-maze model in mice. Biological and Pharmaceutical Bulletin 2005 28 9 1621 1625 2-s2.0-24944549040 10.1248/bpb.28.1621 (Pubitemid 41324120)
36. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskaya I. G., Cattaneo E., Ferrante R. J., Kristal B. S., Friedlander R. M., Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America 2003 100 18 10483 10487 2-s2.0-0041335559 10.1073/pnas.1832501100 (Pubitemid 37071904)
37. Kim J. H., Kim S., Yoon I. S., Lee J. H., Jang B. J., Jeong S. M., Lee J. H., Lee B. H., Han J. S., Oh S., Kim H. C., Park T. K., Rhim H., Nah S. Y., Protective effects of ginseng saponins on 3-nitropropionic acid-induced striatal degeneration in rats. Neuropharmacology 2005 48 5 743 756 2-s2.0-20144389219 10.1016/j.neuropharm.2004.12.013 (Pubitemid 40462413)
38. Wu J., Jeong H. K., Bulin S. E., Kwon S. W., Park J. H., Bezprozvanny I., Ginsenosides protect striatal neurons in a cellular model of Huntington's disease. Journal of Neuroscience Research 2009 87 8 1904 1912 2-s2.0-66049095622 10.1002/jnr.22017
39. Shah Z. A., Gilani R. A., Sharma P., Vohora S. B., Cerebroprotective effect of Korean ginseng tea against global and focal models of ischemia in rats. Journal of Ethnopharmacology 2005 101 1-3 299 307 2-s2.0-24644489772 10.1016/j.jep.2005.05.002 (Pubitemid 41265637)
40. Zheng G. Q., Cheng W., Wang Y., Wang X. M., Zhao S. Z., Zhou Y., Liu S. J., Wang X. T., Ginseng total saponins enhance neurogenesis after focal cerebral ischemia. Journal of Ethnopharmacology 2011 133 2 724 728 2-s2.0-78651408055 10.1016/j.jep.2010.01.064
41. Jung J. S., Shin J. A., Park E. M., Lee J. E., Kang Y. S., Min S. W., Kim D. H., Hyun J. W., Shin C. Y., Kim H. S., Anti-inflammatory mechanism of ginsenoside Rh1 in lipopolysaccharide- stimulated microglia: critical role of the protein kinase A pathway and hemeoxygenase-1 expression. Journal of Neurochemistry 2010 115 6 1668 1680 2-s2.0-78649993974 10.1111/j.1471-4159.2010. 07075.x
42. Park J. S., Park E. M., Kim D. H., Jung K., Jung J. S., Lee E. J., Hyun J. W., Kang J. L., Kim H. S., Anti-inflammatory mechanism of ginseng saponins in activated microglia. Journal of Neuroimmunology 2009 209 1-2 40 49 2-s2.0-64549126462 10.1016/j.jneuroim.2009.01.020
43. Zhu J., Jiang Y., Wu L., Lu T., Xu G., Liu X., Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia. Neuroscience 2012 202 342 351 10.1016/j. neuroscience.2011.11.070
44. Son H. Y., Han H. S., Jung H. W., Park Y. K., Panax notoginseng attenuates the infarct volume in rat ischemic brain and the inflammatory response of microglia. Journal of Pharmacological Sciences 2009 109 3 368 379 2-s2.0-67249152098 10.1254/jphs.08197FP
45. Korea Food and Drug Administration, Korea Food and Drug Administration, Korea Food Code 2007 Seoul, Republic of Korea Mun-Young
46. Huang Q. Y., Wei C., Yu L., Coelho J. E., Shen H. Y., Kalda A., Linden J., Chen J. F., Adenosine A2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation. Journal of Neuroscience 2006 26 44 11371 11378 2-s2.0-33750940225 10.1523/JNEUROSCI.1907- 06.2006 (Pubitemid 44772166)
47. Fernagut P. O., Diguet E., Stefanova N., Biran M., Wenning G. K., Canioni P., Bioulac B., Tison F., Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience 2002 114 4 1005 1017 2-s2.0-0036837148 10.1016/S0306-4522(02)00205-1
48. Franklin K. J. B., Paxions G., The Mouse Brain in Stereotaxic Coordinates 2008 San Diego, Calif, USA Elsevier Academic Press
49. Cho I. H., Hong J., Suh E. C., Kim J. H., Lee H., Lee J. E., Lee S., Kim C. H., Kim D. W., Jo E. K., Lee K. E., Karin M., Lee S. J., Role of microglial IKK β in kainic acid-induced hippocampal neuronal cell death. Brain 2008 131 11 3019 3033 2-s2.0-55749113001 10.1093/brain/awn230
50. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001 25 4 402 408 2-s2.0-0035710746 10.1006/meth.2001.1262 (Pubitemid 34164012)
51. Mestre C., Pelissier T., Fialip J., Wilcox G., Eschalier A., A method to perform direct transcutaneous intrathecal injection in rats. Journal of Pharmacological and Toxicological Methods 1994 32 4 197 200 2-s2.0-0028558934 10.1016/1056-8719(94)90087-6
52. Jang M., Jung H.-S., Kim S.-H., Cho I.-H., Ethyl pyruvate attenuates formalin-induced inflammatory nociception by inhibiting neuronal ERK phosphorylation. Molecular Pain 2012 8, article 40 10.1186/1744-8069-8-40
53. Chen X. C., Zhou Y. C., Chen Y., Zhu Y. G., Fang F., Chen L. M., Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacologica Sinica 2005 26 1 56 62 2-s2.0-11844268081 10.1111/j.1745-7254.2005.00019.x (Pubitemid 40093241)
54. Ge K. L., Chen W. F., Xie J. X., Wong M. S., Ginsenoside Rg1 protects against 6-OHDA-induced toxicity in MES23.5 cells via Akt and ERK signaling pathways. Journal of Ethnopharmacology 2010 127 1 118 123 2-s2.0-72149127646 10.1016/j.jep.2009.09.038
55. Gu M., Gash M. T., Mann V. M., Javoy-Agid F., Cooper J. M., Schapira A. H. V., Mitochondrial defect in Huntington's disease caudate nucleus. Annals of Neurology 1996 39 3 385 389 2-s2.0-0029875381 10.1002/ana.410390317 (Pubitemid 26100764)
56. Browne S. E., Bowling A. C., MacGarvey U., Baik M. J., Berger S. C., Muqit M. M. K., Bird E. D., Beal M. F., Oxidative damage and metabolic dysfunction in huntington's disease: selective vulnerability of the basal ganglia. Annals of Neurology 1997 41 5 646 653 2-s2.0-0030919567 10.1002/ana.410410514 (Pubitemid 27212659)
57. Tabrizi S. J., Cleeter M. W. J., Xuereb J., Taanman J.-W., Cooper J. M., Schapira A. H. V., Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Annals of Neurology 1999 45 1 25 32 10.1002/1531-8249(199901)45: 1<25::AID-ART6>3.0.CO;2-E (Pubitemid 29036428)
58. Panov A. V., Gutekunst C. A., Leavitt B. R., Hayden M. R., Burke J. R., Strittmatter W. J., Greenamyre J. T., Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience 2002 5 8 731 736 2-s2.0-0036327065 10.1038/nn884 (Pubitemid 34827590)
59. Beal M. F., Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology 2005 58 4 495 505 2-s2.0-25444474703 10.1002/ana.20624 (Pubitemid 41377212)
60. Brouillet E., Jacquard C., Bizat N., Blum D., 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. Journal of Neurochemistry 2005 95 6 1521 1540 2-s2.0-29144468251 10.1111/j.1471-4159.2005.03515.x (Pubitemid 41804051)
61. Chen M., Ona V. O., Li M., Ferrante R. J., Fink K. B., Zhu S., Bian J., Guo L., Farrell L. A., Hersch S. M., Hobbs W., Vonsattei J. P., Cha J. H. J., Friedlander R. M., Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Medicine 2000 6 7 797 801 2-s2.0-0033912716 10.1038/77528 (Pubitemid 30469429)
62. Hsieh C. C., Papaconstantinou J., The effect of aging on p38 signaling pathway activity in the mouse liver and in response to ROS generated by 3-nitropropionic acid. Mechanisms of Ageing and Development 2002 123 11 1423 1435 2-s2.0-0036757263 10.1016/S0047-6374(02)00084-2 (Pubitemid 35341150)
63. Hsieh C. C., Rosenblatt J. I., Papaconstantinou J., Age-associated changes in SAPK/JNK and p38 MAPK signaling in response to the generation of ROS by 3-nitropropionic acid. Mechanisms of Ageing and Development 2003 124 6 733 746 2-s2.0-0037674756 10.1016/S0047-6374(03)00083-6 (Pubitemid 36645042)
64. Kulisz A., Chen N., Chandel N. S., Shao Z., Schumacker P. T., Mitochondrial ROS initiate phosphorylation of p38 MAP kinase during hypoxia in cardiomyocytes. American Journal of Physiology 2002 282 6 L1324 L1329 2-s2.0-0036080832 (Pubitemid 34654589)
65. Juo P., Kuo C. J., Reynolds S. E., Konz R. F., Raingeaud J., Davis R. J., Biemann H. P., Blenis J., Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Molecular and Cellular Biology 1997 17 1 24 35 2-s2.0-0031015043 (Pubitemid 26425591)
66. Bezprozvanny I., Hayden M. R., Deranged neuronal calcium signaling and Huntington disease. Biochemical and Biophysical Research Communications 2004 322 4 1310 1317 2-s2.0-4444302167 10.1016/j.bbrc.2004.08.035 (Pubitemid 39164659)
67. Cattaneo E., Calabresi P., Mutant huntingtin goes straight to the heart. Nature Neuroscience 2002 5 8 711 712 2-s2.0-0036321148 10.1038/nn0802-711 (Pubitemid 34827581)
68. Camandola S., Mattson M. P., NF- B as a therapeutic target in neurodegenerative diseases. Expert Opinion on Therapeutic Targets 2007 11 2 123 132 2-s2.0-33846675520 10.1517/14728222.11.2.123 (Pubitemid 46188809)
69. Malek R., Borowicz K. K., Jargiello M., Czuczwar S. J., Role of nuclear factor kappaB in the central nervous system. Pharmacological Reports 2007 59 1 25 33 (Pubitemid 46522699)
70. Cechetto D. F., Role of nuclear factor kappa B in neuropathological mechanisms. Progress in Brain Research 2001 132 391 404 2-s2.0-0035783530 10.1016/S0079-6123(01)32090-3 (Pubitemid 35469063)